论文部分内容阅读
对重症再生障碍性贫血患者进行治疗时,如果有小于40岁、HLA 适合的同胞供髓,则应首选骨髓移植(BMT),在小儿科,估计约90%可得到治愈。为此,需研究扩大 BMT 的适应证。下面,拟围绕小儿患者加以说明。一、适应证1.重症度再生障碍性贫血重症度的分类,有各种各样的提法,以 BMT 为前提的 Ca-mitta 等的分类为世界所采用。日本,以此为基础多采用特发性造血障碍调查研究班的重症度分类法,发病初期为轻症,但后来也符合重症的标准,也适应 BMT。
In the treatment of patients with severe aplastic anemia, bone marrow transplantation (BMT) is preferred if HLA-eligible siblings are under 40 years of age and in pediatrics, an estimated 90% cure is achieved. To this end, need to study the expansion of BMT indications. Below, it is intended to illustrate the pediatric patients. First, the indications 1. The severity of aplastic anemia severity classification, there are a variety of references to BMT as a prerequisite for the classification of Ca-mitta used by the world. Japan, as the basis for more use of idiopathic hematopoietic disorders research class severity classification, early onset of mild, but later also meet the critically ill standard, but also to adapt to BMT.